Osteoporosis Treatment Guidelines

Introduction to Osteoporosis Treatment

For patients with swallowing difficulties and gastrointestinal conditions, injectable denosumab (60mg subcutaneously every 6 months) is recommended as the first-line medication for osteoporosis treatment, as suggested by the American College of Rheumatology 1

Assess 10-year fracture probability using the FRAX tool, as recommended by the American College of Rheumatology 1, 2
Consider vertebral fracture assessment or spinal X-rays to identify existing fractures, according to the American College of Rheumatology 2
Evaluate serum total testosterone as part of pre-treatment evaluation, and consider hormone replacement therapy in men with low levels of total or free serum testosterone, as recommended by the American Urological Association and the Endocrine Society, and supported by Nature Reviews Rheumatology 1
Identify high-risk patients, including those with prior fragility fracture, men aged ≥70 years, men aged 50-69 with risk factors (prior fracture, low body weight, smoking), and men with T-scores ≤-2.5, as suggested by the American College of Rheumatology and supported by Nature Reviews Rheumatology 1

Oral bisphosphonates (alendronate or risedronate) are the first-line pharmacologic treatment for men with osteopenia who are at high risk for fracture, as recommended by the American College of Physicians and supported by evidence from the Annals of Internal Medicine and Nature Reviews Rheumatology 3, 1
Denosumab has demonstrated significant benefits for bone mineral density (BMD) in men with osteoporosis, with improvements in lumbar spine (+5.80%, 95% CI 3.5-8.1), femoral neck (+2.07%, 95% CI 1.23-2.92), and total hip (+2.28%, 95% CI 1.51-3.04), as reported by the American College of Rheumatology 1
Zoledronic acid (IV bisphosphonate) is administered as annual IV infusion, bypasses GI tract, and is effective for BMD improvement in men, with improvements in lumbar spine (+6.10%, 95% CI 4.99-7.21), femoral neck (+3.1%, 95% CI 2.2-5.4), and total hip (+3.8%, 95% CI 2.2-5.4), as reported by the American College of Rheumatology 1
Teriparatide (anabolic agent) is a daily subcutaneous injection, but is contraindicated in patients with skeletal malignancies and limited to 2 years of treatment, as noted by the Endocrine Society 1
Abaloparatide can be considered as first-line treatment in men with osteopenia, as recommended by the Endocrine Society and supported by Nature Reviews Rheumatology 1

Ensure adequate calcium intake (1200 mg/day) and vitamin D3 (800-1000 IU/day), as recommended by the National Comprehensive Cancer Network 4 and the National Osteoporosis Foundation 1
Check 25-hydroxy vitamin D levels before initiating therapy, according to the European Society for Clinical Nutrition and Metabolism 5
Recommend regular weight-bearing and resistance exercise, as suggested by the American College of Sports Medicine and supported by Nature Reviews Rheumatology 1
Advise a balanced diet with adequate protein intake, as recommended by the Academy of Nutrition and Dietetics and supported by Nature Reviews Rheumatology 1

Measure bone turnover markers at baseline and 3 months to assess response, as recommended by the American College of Rheumatology 1
Consider BMD testing after 1-2 years of therapy, as noted by the International Osteoporosis Foundation 1
Use biochemical markers of bone turnover to assess adherence to anti-resorptive therapy, and continue monitoring with serial dual-energy x-ray absorptiometry testing, as recommended by the International Osteoporosis Foundation and supported by Nature Reviews Rheumatology 1
Be aware that up to 64% of men may be non-adherent to bisphosphonate therapy by 12 months, highlighting the need for close monitoring and support, as reported by Nature Reviews Rheumatology 1
Discontinuation of treatment without follow-up can lead to rebound bone loss, as warned by the Annals of Internal Medicine 3